{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:22:15Z","timestamp":1762622535292,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017210","name":"Health Research Institute of Santiago de Compostela","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ijcha.2025.101639","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T08:38:59Z","timestamp":1740818339000},"page":"101639","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Characterization and anticoagulation treatment patterns of hospitalized patients with nonvalvular atrial fibrillation in Spain: The CARISMA registry"],"prefix":"10.1016","volume":"57","author":[{"given":"Lorenzo","family":"F\u00e1cila","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adri\u00e1n","family":"Valverde Tavira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Rilo Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Laskibar Asua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laia","family":"Tirapu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Montagud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"S\u00e1nchez-Serna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eloy","family":"G\u00f3mez-Mariscal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Mainar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Mart\u00edn Dorado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Lorenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Mar\u00eda","family":"Pello L\u00e1zaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mois\u00e9s","family":"Rodr\u00edguez-Ma\u00f1ero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcha.2025.101639_b0005","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.117.309732","article-title":"Atrial fibrillation: epidemiology, pathophysiology, and clinical Outcomes","volume":"120","author":"Staerk","year":"2017","journal-title":"Circ. Res"},{"key":"10.1016\/j.ijcha.2025.101639_b0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/agm2.12015","article-title":"Atrial fibrillation in aging population","volume":"1","author":"Chen","year":"2018","journal-title":"Aging. Med. (milton)"},{"key":"10.1016\/j.ijcha.2025.101639_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1060030","article-title":"Atrial fibrillation: primary prevention, secondary prevention, and prevention of thromboembolic complications: part 1","volume":"10","author":"Trohman","year":"2023","journal-title":"Front. Cardiovasc. Med"},{"issue":"2024","key":"10.1016\/j.ijcha.2025.101639_b0020","first-page":"e1","article-title":"ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2025.101639_b0025","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"RE-LY Steering Committee and Investigators, Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.ijcha.2025.101639_b0030","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"ARISTOTLE Committees and Investigators, Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.ijcha.2025.101639_b0035","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"ROCKET AF Investigators, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.ijcha.2025.101639_b0040","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"ENGAGE AF-TIMI 48 Investigators, Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.ijcha.2025.101639_b0045","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/phar.2158","article-title":"Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017","volume":"38","author":"Zhu","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijcha.2025.101639_b0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.9973","article-title":"Time trends in patient characteristics, anticoagulation treatment, and prognosis of incident nonvalvular atrial fibrillation in the Netherlands","volume":"6","author":"Chen","year":"2023","journal-title":"JAMA Netw. Open"},{"issue":"2021","key":"10.1016\/j.ijcha.2025.101639_b0055","first-page":"373","volume":"42","author":"Hindricks","year":"2020","journal-title":"Eur. Heart. J"},{"key":"10.1016\/j.ijcha.2025.101639_b0060","doi-asserted-by":"crossref","unstructured":"M.C. Polidori, M. Alves, G. Bahat, A.S. Boureau, S. Ozkok, R. Pfister, A. Pilotto, N. Veronese, M. Bo, Special Interest Group \u201cCardiovascular Diseases\u201d of the EuGMS, Atrial fibrillation: a geriatric perspective on the 2020 ESC guidelines, Eur Geriatr Med 13 (2022) 5\u201318. doi: 10.1007\/s41999-021-00537-w.","DOI":"10.1007\/s41999-021-00537-w"},{"key":"10.1016\/j.ijcha.2025.101639_b0065","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/fca-2020-0014","article-title":"GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke","volume":"17","author":"Bassand","year":"2021","journal-title":"Future. Cardiol"},{"key":"10.1016\/j.ijcha.2025.101639_b0070","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ahj.2017.08.011","article-title":"GARFIELD-AF, ORBIT-AF Investigators, International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries","volume":"194","author":"Steinberg","year":"2017","journal-title":"Am. Heart. J"},{"key":"10.1016\/j.ijcha.2025.101639_b0075","first-page":"1139","article-title":"GARFIELD-AF Investigators, Characteristics, treatment, and outcomes of newly diagnosed atrial fibrillation patients with heart failure: GARFIELD-AF, ESC","volume":"8","author":"Ambrosio","year":"2021","journal-title":"Heart. Fail"},{"key":"10.1016\/j.ijcha.2025.101639_b0080","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00392-022-02079-y","article-title":"GARFIELD-AF Investigators, GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide","volume":"112","author":"Haas","year":"2023","journal-title":"Clin. Res. Cardiol"},{"key":"10.1016\/j.ijcha.2025.101639_b0085","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.aprim.2020.05.016","article-title":"The use and adherence of oral anticoagulants in Primary Health Care in Catalunya, Spain: A real-world data cohort study","volume":"52","author":"Giner-Soriano","year":"2020","journal-title":"Aten. Primaria"},{"key":"10.1016\/j.ijcha.2025.101639_b0090","article-title":"Real-World Data of Anticoagulant Treatment in Non-valvular Atrial Fibrillation","volume":"8","author":"Calderon","year":"2021","journal-title":"Front. Cardiovasc. Med"},{"key":"10.1016\/j.ijcha.2025.101639_b0095","article-title":"Influence of the COVID-19 pandemic on patients receiving oral anticoagulants for the treatment of non-valvular atrial fibrillation","volume":"51","author":"Com\u00edn Colet","year":"2024","journal-title":"Int. J. Cardiol. Heart. Vasc"},{"key":"10.1016\/j.ijcha.2025.101639_b0100","article-title":"Sex and gender differences in the use of oral anticoagulants for non-valvular atrial fibrillation: A population-based cohort study in primary health care in catalonia","volume":"14","author":"Giner-Soriano","year":"2023","journal-title":"Front. Pharmacol"},{"key":"10.1016\/j.ijcha.2025.101639_b0105","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/bcp.14127","article-title":"Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: A systematic review","volume":"86","author":"Santos","year":"2020","journal-title":"Br. J. Clin. Pharmacol"},{"key":"10.1016\/j.ijcha.2025.101639_b0110","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1080\/14779072.2021.2013816","article-title":"Off-label direct oral anticoagulants dosing in atrial fibrillation and venous thromboembolism is associated with higher mortality","volume":"19","author":"Aguilar","year":"2021","journal-title":"Expert. Rev. Cardiovasc. Ther"},{"key":"10.1016\/j.ijcha.2025.101639_b0115","unstructured":"European Medicines Agency, Pradaxa Summary of Product Characteristics. Accessed at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/pradaxa-epar-product-information_en.pdf (Last update: January 16, 2024), (2009)."},{"key":"10.1016\/j.ijcha.2025.101639_b0120","unstructured":"European Medicines Agency, Xarelto Summary of Product Characteristics. Accessed at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xarelto-epar-product-information_en.pdf (Last update: August 2, 2023), (2009)."},{"key":"10.1016\/j.ijcha.2025.101639_b0125","unstructured":"European Medicines Agency, Eliquis Summary of Product Characteristics. Accessed at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/eliquis-epar-product-information_en.pdf (Last update: March 8, 2024), (2011)."},{"key":"10.1016\/j.ijcha.2025.101639_b0130","unstructured":"European Medicines Agency, Lixiana Summary of Product Characteristics. Accessed at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lixiana-epar-product-information_en.pdf (Last update: January 10, 2024), (2015)."},{"key":"10.1016\/j.ijcha.2025.101639_b0135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ijcha.2025.101639_b0140","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF02982161","article-title":"The I.A.N.A Task Force on frailty assessment of older people in clinical practice","volume":"12","author":"Abellan van Kan","year":"2008","journal-title":"J. Nutr. Health. Aging"},{"key":"10.1016\/j.ijcha.2025.101639_b0145","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3390\/biomedicines11071825","article-title":"Heart Failure and Major Adverse Cardiovascular Events in Atrial Fibrillation Patients: A Retrospective Primary Care Cohort Study","volume":"11","author":"Molt\u00f3-Balado","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ijcha.2025.101639_b0150","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.recesp.2013.03.006","article-title":"Prevalence of undiagnosed atrial fibrillation and of that not being treated with anticoagulant drugs: the AFABE study","volume":"66","author":"Clua-Espuny","year":"2013","journal-title":"Rev. Esp. Cardiol. (engl. Ed)"},{"key":"10.1016\/j.ijcha.2025.101639_b0155","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1111\/bcp.14071","article-title":"Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): A cross-national drug utilization study","volume":"85","author":"Ib\u00e1\u00f1ez","year":"2019","journal-title":"Br. J. Clin. Pharmacol"},{"key":"10.1016\/j.ijcha.2025.101639_b0160","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2217\/fca-2020-0024","article-title":"Santamar\u00eda, investigators of ETNA AF Spain, Use of edoxaban in clinical practice: Comparison of data from the Spanish population in the ETNA-AF-Europe registry","volume":"16","author":"Bar\u00f3n-Esquivias","year":"2020","journal-title":"Future. Cardiol"},{"key":"10.1016\/j.ijcha.2025.101639_b0165","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1186\/s12872-021-02295-w","article-title":"Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends","volume":"21","author":"Shiyovich","year":"2021","journal-title":"BMC. Cardiovasc. Disord"},{"key":"10.1016\/j.ijcha.2025.101639_b0170","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12959-020-00218-x","article-title":"GARFIELD-AF Investigators, Changes in anticoagulant prescription in Dutch patients with recent-onset atrial fibrillation: observations from the GARFIELD-AF registry","volume":"18","author":"Seelig","year":"2020","journal-title":"Thromb. J"},{"key":"10.1016\/j.ijcha.2025.101639_b0175","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.aprim.2017.05.009","article-title":"en nombre de los investigadores del estudio SILVER-AP, [Clinical characteristics of patients with atrial fibrillation treated with direct oral anticoagulants attended in primary care setting. The SILVER-AP study]","volume":"50","author":"de la Figuera","year":"2018","journal-title":"Aten. Primaria"},{"key":"10.1016\/j.ijcha.2025.101639_b0180","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.3390\/jcm12031224","article-title":"RE_BELD Spanish Investigator\u2019s Group, Use of Direct Acting Oral Anticoagulants in Elderly Patients with Atrial Fibrillation: A Multicenter, Cross-Sectional Study in Spain","volume":"12","author":"D\u00edez-Villanueva","year":"2023","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.ijcha.2025.101639_b0185","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1016\/j.hrthm.2020.07.022","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation","volume":"17","author":"Chan","year":"2020","journal-title":"Heart. Rhythm"},{"key":"10.1016\/j.ijcha.2025.101639_b0190","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.amjcard.2020.01.044","article-title":"Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation Who are Indicated for Standard Dosing","volume":"125","author":"Cho","year":"2020","journal-title":"Am. J. Cardiol"},{"key":"10.1016\/j.ijcha.2025.101639_b0195","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.121.007971","article-title":"Off-Label Under- and Overdosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis","volume":"14","author":"Zhang","year":"2021","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.ijcha.2025.101639_b0200","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13819","article-title":"Off-label underdosing of four individual NOACs in patients with nonvalvular atrial fibrillation: A systematic review and meta-analysis of observational studies","volume":"52","author":"Sang","year":"2022","journal-title":"Eur. J. Clin. Invest"},{"key":"10.1016\/j.ijcha.2025.101639_b0205","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.123.010062","article-title":"Off-Label Dosing of Direct Oral Anticoagulants Among Inpatients With Atrial Fibrillation in the United States","volume":"16","author":"Sandhu","year":"2023","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.ijcha.2025.101639_b0210","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s12325-022-02368-y","article-title":"Direct Oral Anticoagulant (DOAC) Dosing in Patients with Non-valvular Atrial Fibrillation (NVAF) in the United Kingdom: A Retrospective Cohort Study Using CPRD Gold Database","volume":"40","author":"Khachatryan","year":"2023","journal-title":"Adv. Ther"},{"key":"10.1016\/j.ijcha.2025.101639_b0215","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40780-020-0157-z","article-title":"Inappropriate direct oral anticoagulant dosing in atrial fibrillation patients is associated with prescriptions for outpatients rather than inpatients: a single-center retrospective cohort study","volume":"6","author":"Miyazaki","year":"2020","journal-title":"J. Pharm. Health. Care. Sci"},{"issue":"2014","key":"10.1016\/j.ijcha.2025.101639_b0220","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"AHA\/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J. Am. Coll. Cardiol"},{"key":"10.1016\/j.ijcha.2025.101639_b0225","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJMra1607714","article-title":"Management of Antithrombotic Therapy after Acute Coronary Syndromes","volume":"384","author":"Rodriguez","year":"2021","journal-title":"N. Engl. J. Med"}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906725000429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906725000429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:17:45Z","timestamp":1762622265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906725000429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":45,"alternative-id":["S2352906725000429"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2025.101639","relation":{},"ISSN":["2352-9067"],"issn-type":[{"type":"print","value":"2352-9067"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization and anticoagulation treatment patterns of hospitalized patients with nonvalvular atrial fibrillation in Spain: The CARISMA registry","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2025.101639","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101639"}}